Brillant Blue Versus Indocyanine Green for Macular Hole Surgery
NCT ID: NCT00757471
Last Updated: 2016-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2008-08-31
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trypan Blue Versus Brillant Blue for Epiretinal Membranes
NCT00757380
Brilliant Blue Versus Indocyanine Green
NCT01083004
Infracyanine Green vs Brilliant Blue G in Macular Hole Inverted Flap Surgery: A Swept Source OCT Analysis.
NCT03946267
Membrane Blue Versus Infracyanine Green
NCT00555269
Effect of the Membrane Blue Dual® Dye on the Retinal Sensitivity in Macular Hole Surgery
NCT02894424
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Brillant Blue
Brillant Blue
Membrane Peeling with Brillant Blue
Group 2
Indocyanine Green
Indocyanine Green
Membrane Peeling with indocyanine Green
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Brillant Blue
Membrane Peeling with Brillant Blue
Indocyanine Green
Membrane Peeling with indocyanine Green
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stage 2 macular holes, followed up for at least 6 months
* Pseudophakic and phakic eyes
* Age over 60 years
Exclusion Criteria
* Secondary macular holes
* Severe ocular diseases
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Christiane I. Falkner-Radler
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Katharina Kreppler, MD
Role: STUDY_CHAIR
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Christiane I Falkner-Radler, MD
Role: PRINCIPAL_INVESTIGATOR
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser surgery
Vienna, Vienna, Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FR-5-CI-2008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.